Investment Rating - Industry rating: Outperform the market (maintained rating) [11] Core Views - The pig sector shows a divergence between pig prices and piglet prices, with pig prices rebounding while piglet prices continue to decline. The average price of pigs is 14.87 CNY/kg, up 1.09% from last week, with an average profit of approximately 225 CNY per head for self-breeding and self-raising operations [1][15] - The poultry sector is experiencing low valuations and elasticity, particularly in the white chicken segment, where supply pressures are exacerbated by restrictions on overseas breeding imports due to avian influenza outbreaks [3][17] - The feed sector is recommended for investment due to a fundamental turning point and relatively low valuations, with Hai Da Group highlighted as a key player [5][21] Summary by Sections Pig Sector - Pig prices have rebounded, with an average price of 14.87 CNY/kg as of February 22, 2025, while piglet prices are declining, indicating a potential short-term weakness in piglet pricing [1][15] - Supply remains low with an average slaughter weight of 125.68 kg, and the proportion of pigs over 150 kg is 4.11% [1][15] - The sector is considered undervalued, with major companies like Muyuan Foods and Wens Foodstuffs having head valuations below 2000 CNY per head, suggesting potential for recovery [2][16] Poultry Sector - The white chicken segment faces supply pressure due to halted overseas breeding imports, leading to a significant drop in domestic breeding stock [3][17] - Chicken prices have stabilized, with the average price for live chickens at 2.80 CNY per bird, and expectations for price recovery as processing plants resume operations [3][17] - Investment recommendations include Shengnong Development and other companies in the poultry sector due to anticipated demand recovery [4][18] Feed Sector - Hai Da Group is highlighted as a key investment opportunity due to improving market conditions in aquaculture feed after a prolonged downturn [5][21] - The prices of various aquatic products have shown a mixed trend, with some prices increasing due to supply constraints [5][21] Seed and Agricultural Technology - The application of genetically modified technology is expected to accelerate, enhancing the competitiveness of leading seed companies [7][23] - The low-altitude economy is identified as a growth area, with significant potential for agricultural applications of drones [7][23] Pet Sector - Domestic pet brands are rapidly growing, with significant sales increases in pet food, indicating a robust market for local brands [9][25] - Pet food exports have also seen substantial growth, reflecting a healthy export market [9][25] - Recommended companies in the pet sector include Guibao Pet and Zhongchong Co., Ltd. due to their strong market positions [9][27]

Investment Rating - The report maintains a "Market Perform" rating for the agriculture, forestry, animal husbandry, and fishery industry [2] Core Insights - The agriculture, forestry, animal husbandry, and fishery industry underperformed the market in February, with a 0.20% increase compared to the Shanghai Composite Index's 2.16% increase [12][8] - The report highlights that the pig farming sector is expected to maintain profitability in 2025, supported by favorable policies and a gradual recovery in pig inventory [49][50] - The poultry farming sector, particularly white feather chicken, is anticipated to see marginal price improvements as the macroeconomic environment stabilizes [52] - The feed and animal health sectors are projected to experience performance recovery as pig inventory gradually increases [53] Summary by Sections Market Review - The agriculture, forestry, animal husbandry, and fishery industry index ranked 25th among 31 industry indices in February, with a year-to-date decline of 2.79% [12][8] - The sub-sectors of fruit and vegetable processing, comprehensive III, and grain and oil processing showed positive growth, while pet food and poultry farming lagged behind [13] Pig Farming - In February, the average price of external three yuan pigs decreased by 6.80% month-on-month, while the average price of external three yuan piglets increased by 21.91% [20] - The average profit for self-bred pigs was approximately 37.35 yuan per head, while for purchased piglets, it was 10.95 yuan per head [20] Poultry Farming - The average price of white feather chicken in February was 6.05 yuan per kilogram, down 18.34% month-on-month [34] - The average price of meat chicken seedlings was 2.12 yuan per chick, down 19.67% month-on-month [34] Fisheries - In February, the prices of various freshwater fish remained stable, while the price of shrimp decreased by 11.11% [45] Investment Recommendations - The report suggests maintaining a focus on high-quality pig farming companies such as Muyuan Foods and Wens Foodstuffs, which are expected to continue generating profits in 2025 [49][52] - The report recommends attention to the feed sector as a post-cycle investment opportunity, particularly in leading companies like Haida Group [53] - In the seed industry, companies with strong research capabilities are highlighted as key players, including Dabeinong and Longping High-Tech [54] - The pet food sector is expected to grow, with recommendations to monitor companies like Guobao Pet and Zhongchong Co., which are expanding their market presence [56]

Investment Rating - Industry rating: Outperform the market (maintained rating) [10] Core Insights - The Central Document No. 1 emphasizes "new agricultural productivity" and the need for rural revitalization, highlighting the importance of food security and the promotion of biotechnology and smart agriculture [1][14] - The report identifies key investment opportunities in various sectors, including seeds, low-altitude economy, infrastructure, and animal husbandry [2][3][4][5][6] Seed Sector - The document mentions "food" 15 times, stressing national food security and the need to enhance crop yields through biotechnology [2][14] - The commercialization of genetically modified corn is expected to accelerate, benefiting leading seed companies [2] - Recommended companies include Longping High-Tech, Dabeinong, and Quanyin High-Tech [2] Low-Altitude Economy - The report supports the development of smart agriculture and low-altitude technologies, predicting a trillion-yuan market by 2030 [2][15] - Applications of drones in agriculture are expected to grow, benefiting companies involved in agricultural drone technology [2] Infrastructure - Emphasis on soil protection and quality improvement, with initiatives for high-standard farmland construction and water conservancy projects [2][15] - Quality enterprises in agriculture, fertilizers, and agricultural reclamation are expected to benefit [2] Swine Sector - The average price of live pigs is stable at 14.67 yuan/kg, with a decrease in profitability for self-breeding farms [3][16] - The supply of pigs is expected to remain high, while demand is sluggish post-Spring Festival [3][16] - Recommended companies include Wens Foodstuffs, Muyuan Foods, and New Hope Liuhe [3][17] Poultry Sector - The report highlights the impact of restricted overseas breeding on supply, with a significant drop in domestic breeding stock [4][19] - Chicken prices have rebounded, with recommendations for companies like Shengnong Development and Yisheng Livestock [4][19] Feed Sector - Hai Da Group is recommended due to its improving fundamentals and relative valuation [6][21] - The report notes a potential recovery in the aquaculture feed market after a prolonged downturn [6][21] Animal Health Sector - The report emphasizes new market opportunities in pet health products and the introduction of innovative vaccines [7][22] - Recommended companies include Kexin Biological and Zhongmu Biological [7][22] Pet Sector - Domestic pet brands are growing rapidly, with a notable increase in pet food exports [8][24] - Recommended companies include Guibao Pet, Zhongchong Co., and Petty Co. [8][24]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The animal health industry is undergoing structural changes driven by the transformation of the breeding structure, making innovation in products imperative. The company is positioned to leverage its leading research and development capabilities to create competitive animal health products, with three core products leading the market in terms of market share. The company has a comprehensive pipeline of products under development, with a rich reserve of combination vaccines, including the imminent launch of the pig fever and pseudorabies combination vaccine. The report is optimistic about the company's second growth phase driven by multi-valent vaccines and recommends it as a key investment opportunity [2][4][13]. Summary by Sections Industry Overview - Since 2010, the animal health industry has rapidly grown due to the implementation of mandatory immunization policies and the market release of large single products. The industry scale reached 16.3 billion yuan in 2023, significantly influenced by breeding cycles. The industry faces challenges such as severe price pressure due to product homogeneity and declining profitability. Innovation is identified as the biggest challenge, with a pressing need for differentiated products with high added value [5][14][16]. Company Strengths - The company has established itself as a leader in the animal vaccine industry, with comprehensive R&D capabilities that place it in the top tier. It has successfully implemented a collaborative model with higher education institutions, enhancing its research capabilities. The management team has extensive experience in vaccine R&D, production, and sales, contributing to the company's competitive edge [6][46]. Product Pipeline and Innovations - The company has a robust pipeline of products under development, focusing on multi-valent vaccines, genetic engineering vaccines, and pet vaccines. The pig fever and pseudorabies combination vaccine is set to launch in 2025, with expectations for significant market penetration and revenue growth. The company is also preparing to introduce additional combination vaccines targeting other diseases in the coming years [7][40][41]. Market Dynamics - The market for animal vaccines is evolving, with a notable shift towards multi-valent and genetic engineering vaccines. The company is well-positioned to capitalize on these trends, as it has a strong reserve of combination vaccine projects and is entering a period of intensive new product launches. The increasing scale of pig farming has strengthened the bargaining power of breeding enterprises, leading to a more favorable competitive landscape for leading animal health companies [20][27][36].

证券代码：688526 证券简称：科前生物 公告编号：2025-006 新兽药名称：牛支原体活疫苗（HB150 株） 英文名：Mycoplasma bovis Vaccine, Live (Strain HB150) 新兽药注册证书号：（2025）新兽药证字 11 号 武汉科前生物股份有限公司 关于获批新兽药注册证书的自愿性信息披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共 和国农业农村部审查，批准公司申报的牛支原体活疫苗（HB150 株） 为新兽药，并核发《新兽药注册证书》，具体详情如下： 一、新兽药的基本信息 牛支原体（Mycoplasma bovis，M. bovis）是一种导致牛呼吸系 统疾病的重要病原；除肺炎外，还可导致乳腺炎、关节炎、中耳炎、 角膜结膜炎、生殖道炎症、流产与不孕等。该病在世界范围内存在， 欧洲每年约有 1/3 的犊牛肺炎是由牛支原体引起的。我国于 2008 年 首次报道肉牛的牛支原体肺炎，至今已发现在全国普遍流行，肉牛和 奶牛 ...

Financial Performance - In 2024, the company achieved total operating revenue of RMB 947.87 million, a decrease of 10.92% compared to the previous year[4] - The net profit attributable to shareholders was RMB 375.08 million, down 5.27% year-on-year[4] - Basic earnings per share decreased to RMB 0.80, down 5.88% from RMB 0.85 in the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 4.49 billion, a decrease of 3.96% from the beginning of the year[5] - Shareholders' equity attributable to the company increased by 2.56% to RMB 3.93 billion[5] Market Conditions - The company is facing intensified market competition, leading to a decline in revenue and net profit[6] - As of the end of 2024, the national pig inventory was 427.43 million heads, a decrease of 1.6% year-on-year[6] Research and Development - The company is increasing its R&D efforts to accelerate new product development and enhance market competitiveness[6] Financial Reporting - The financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[9] - Investors are advised to be aware of potential risks related to the preliminary financial data[9]

证券代码：688526 证券简称：科前生物 公告编号：2025-004 武汉科前生物股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。。 重要内容提示： | 回购方案首次披露日 | 2024/2/3，由实际控制人何启盖先生、方六荣女士、 | | --- | --- | | | 吴美洲先生、吴斌先生提议 | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 3,000 万元~5,000 万元 | | 回购价格上限 | 19.57 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 2,211,573 股 | | 实际回购股数占总股本比例 | 0.4745% | | 实际回购金额 | 3,583.58 万元 | | 实际回购价格区间 | 12.80 元/股~18.90 元/股 | 注：回购方案披露时的回购价格上限为 20 元/股 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-003 武汉科前生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份情况公告如下： 截至 2025 年 1 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 2,211,573 股，占公司总股本 466,128,056 股的比例为 0.4745%，回购成交的最高价为 18.90 元/股，最低价为 12.80 元/股，支付的资金 总额为人民币 35,835,843.30 元（不含印花税、交易佣金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 重要内容提示： | 回购方案首次披露日 | 2024/2/3，由实际控制人何启盖先生、方 ...

一、监事会会议召开情况 证券代码：688526 证券简称：科前生物 公告编号：2024-063 武汉科前生物股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 特此公告。 武汉科前生物股份有限公司监事会 武汉科前生物股份有限公司（下称"公司"）于 2024 年 12 月 9 日以通讯表决的形式召开第四届监事会第六次会议（下称"本次会 议"）。本次会议通知于 2024 年 12 月 4 日以邮件、电话的方式向各 位监事发出，本次会议由监事会主席吴斌先生主持，本次会议应参与 表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、召开程序 均符合《公司法》、《证券法》等法律、法规和规范性文件以及《公 司章程》的规定。 二、监事会会议审议情况 体发展方向，本次关联交易的审批程序合法合规，不存在损害公司及 股东利益的情形。 具 体 内 容 详 见 公 司 于 同 日 刊 登 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《武汉科前生物股份有限公司关于拟与华 ...

证券代码：688526 证券简称：科前生物 公告编号：2024-064 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科前 生物"或"公司"）经与华中农业大学（下称"华中农大"）竞争性 谈判，取得了鸡传染性鼻炎（A 型+B 型+C 型，重组蛋白）、鸡滑液囊 支原体、鸡毒支原体三联灭活疫苗（HB03 株+HB15 株），重组新城疫 病毒、传染性支气管炎病毒、禽流感病毒（H9 亚型）、传染性法氏囊 病重组杆状病毒、禽腺病毒（I 群，4 型）五联灭活疫苗（VII XF 株 +rRBD 蛋白+JS 株+WF 株+HB-2 株），鸡滑液囊支原体、鸡毒支原体、 鸡传染性支气管炎三联灭活疫苗，鸭副黏病毒病、禽流感（H9 亚型）、 鸭坦布苏病毒病、鸭腺病毒病（3 型）四联灭活疫苗（AN20 株+HB19 株+DF2 株+rFiber2），鸡滑液囊支原体、鸡毒支原体二联灭活疫苗， 新型 ...